Document:

Exhibit 4.1

 

DESCRIPTION
OF the registrant’s securities registered pursuant to section 12

of the securities exchange act of 1934

 

General

 

The
descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended
and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and
amended and restated bylaws that are currently in effect.

 

Our
amended and restated certificate of incorporation provides for Common Stock and preferred stock, the rights, preferences and privileges
of which may be designated from time to time by our board of directors.

 

Our
authorized capital stock consists of 110,000,000 shares, all with a par value of $0.001 per share, of which 100,000,000 shares
are designated as Common Stock and 10,000,000 shares are designated as preferred stock.

 

Common
Stock

 

The
holders of our Common Stock are entitled to one vote per share on all matters submitted to a vote of our stockholders. Subject
to preferences that may be applicable to any preferred stock outstanding at the time, the holders of outstanding shares of Common
Stock are entitled to receive ratably any dividends declared by our board of directors out of assets legally available therefor.
In the event that we liquidate, dissolve or wind up, holders of our Common Stock are entitled to share ratably in all assets remaining
after payment of liabilities and the liquidation preference of any then outstanding shares of preferred stock. Holders of Common
Stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions
applicable to the Common Stock. As discussed in “Risk Factors” above, certain provisions in our amended and restated
certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other
change of control involving us that our stockholders may consider favorable. All outstanding shares of Common Stock are fully
paid and non-assessable.

 

Except
as otherwise required by Delaware law, all stockholder action, other than the election of directors or certain amendments of our
amended and restated certificate of incorporation, is taken by the vote of a majority of the voting power of the shares present
in person or represented by proxy at the meeting and entitled to vote on the subject matter, at a meeting in which a quorum, consisting
of a majority of the outstanding shares of Common Stock is present in person or by proxy. The election of directors by our stockholders
is determined by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and entitled
to vote, at a meeting held for such purposes at which a quorum, consisting of a majority of the outstanding shares of Common Stock,
is present in person or by proxy. Certain amendments to our amended and restated certificate of incorporation require the approval
of holders of at least sixty-six and two-third percent (66 2/3%) of the voting power of all then-outstanding shares of our Common
Stock entitled to vote generally in the election of directors, voting together as a single class.

 

We
have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any
future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash
dividends on our Common Stock for the foreseeable future. Any future determination related to our dividend policy will be made
at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition,
capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.

 

Preferred
Stock

 

Our
amended and restated certificate of incorporation provides that our board of directors may, without further action by our stockholders,
fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred stock in one
or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion
rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting
any series or the designation of such series, any or all of which may be greater than the rights of our Common Stock. The issuance
of our preferred stock could adversely affect the voting power of holders of our Common Stock and the likelihood that such holders
will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect
of delaying, deferring or preventing a change of control or other corporate action. We have no present plan to issue any shares
of preferred stock.

 

     

     

    

 

Description
of the Warrants

 

Common
Stock Warrants Issued in July 2019 Equity Offering (“July 2019 Warrant”)

 

On
July 16, 2019, in connection with a secondary public offering of shares of the Company’s Common Stock, the Company issued
to H.C. Wainwright & Co., LLC, as placement agent, a warrant to purchase 8,334 shares of Common Stock. The warrant was issued
in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation
D promulgated thereunder. Terms used but not otherwise defined herein will have the meaning given them in the warrant, attached
as Exhibit 4.1 to our Form 8-K filed on July 17, 2019.

 

Duration
and Exercise Price. The warrant has an exercise price of $33.75 per share and will expire July 11, 2024.

 

Adjustment.
For so long as the warrant remains outstanding, the exercise price and number of shares of Common Stock issuable upon exercise
of the warrant is subject to adjustment as follows: (a) upon payment of a stock dividend or other distribution on a class or series
of shares Common Stock, not including shares issued under this warrant; (b) upon subdivision (by stock spilt, stock dividend,
recapitalization, or otherwise) or combination (by reverse stock split or otherwise) of shares of Common Stock; or (c) upon the
issuance of any shares of capital stock by reclassification of shares of the Common Stock.

 

Rights
upon Distribution of Assets. In the event that the Company declares or makes any dividend or other distribution of its assets
to holders of its Common Stock, the warrant holder will be entitled to participate in such distribution to the same extent that
such holder would have participated therein if the holder had held the number of shares of Common Stock acquirable upon exercise
of the warrant.

 

Fundamental
Transaction. In the event of a Fundamental Transaction, as described in the warrant and generally including the sale, transfer
or other disposition of all or substantially all of our properties or assets; our consolidation or merger with or into another
person or reorganization; a recapitalization, reorganization or reclassification in which our Common Stock is converted into other
securities, cash or property; or any acquisition of our outstanding Common Stock that results in any person or group becoming
the beneficial owner of 50% of the voting power represented by our outstanding Common Stock, then the holders of the warrant will
be entitled to receive upon exercise of the warrant the kind and amount of securities, cash, assets or other property that the
holders would have received had they exercised the warrant immediately prior to such Fundamental Transaction. Subject to certain
limitations, in the event of a Fundamental Transaction the warrant holder may at its option require the Company or any Successor
Entity to purchase the warrant from the holder by paying to the holder an amount of cash equal to the Black Scholes Value of the
remaining unexercised portion of the warrant on the date of the consummation of the Fundamental Transaction.

 

Purchase
Right. Any time that the Company grants, issues, or sells any securities pro rata to all of the record holders of the Common
Stock (the “July 2019 Purchase Right”), the holder of the warrant will be entitled to acquire the aggregate July 2019
Purchase Rights that the holder could have acquired if the holder had held the number of shares of Common Stock acquirable upon
exercise of the warrant. However, to the extent that an exercise of the July 2019 Purchase Right would exceed the Beneficial Ownership
Limitation (defined below), then to such extent the July 2019 Purchase Right will be held in abeyance until such time, if ever,
that complete exercise of the July 2019 Purchase Right would not exceed the Beneficial Ownership Limitation.

 

Transferability.
Subject to applicable laws and restrictions on transfer, the warrant may be transferred at the option of the holder. The warrant
is not listed on any securities exchange or nationally recognized trading system.

 

Exercisability.
After the Initial Exercisability Date, the warrant will be exercisable, at the option of each holder, in whole or in part, by
delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased
upon such exercise. If, at the time a holder exercises its warrant (but not sooner than six months following the date of the warrant),
a registration statement registering the issuance of the shares of Common Stock underlying the warrant under the Securities Act
is not then effective or available, nor is any current prospectus thereto available, and an exemption from registration under
the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such
exercise (either in whole or in part) the number of shares of Common Stock determined according to a formula set forth in the
warrant.

 

Limitations
on Exercise. A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder
would own more than 4.99% of the outstanding Common Stock after exercise (the “Beneficial Ownership Limitation”),
except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the Beneficial Ownership
Limitation up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the warrants. No fractional shares of Common Stock
will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will either pay the holder an amount
in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.

 

    2

     

    

 

Right
as a Stockholder. Except as otherwise provided in the warrant or by virtue of such holder’s ownership of shares of our
Common Stock, the holders of the warrant do not have the rights or privileges of holders of our Common Stock, including any voting
rights, unless and until they exercise their warrant.

 

Waivers
and Amendments. Subject to certain exceptions, any term of the warrant may be amended or waived with our written consent and
the written consent of the holders.

 

Compensation
for Buy-In on Failure to Timely Deliver Securities. Upon exercise of the warrant by the holder, if the Company fails to cause
its transfer agent to deliver the securities to holder by the required share delivery date set forth in the warrant, and as result
the holder or the holder’s broker must purchase shares of Common Stock in satisfaction of a sale by the holder of Common
Stock that the holder anticipated receiving upon an exercise of the warrant (a “July 2019 Buy-In”), then, generally,
the holder may require the Company to (1) pay to the holder the difference, if any, between the price at which the holder or its
broker purchased Common Stock to cover the July 2019 Buy-In and the price at which the same number of shares could have been purchased
under the warrant and (2) at the option of the holder, either reinstate the portion of the warrant that the holder exercised and
the Company failed to honor or issue the number of shares requested in such exercise.

 

Common
Stock Warrants Issued in August 2018 Rights Offering

 

On
August 13, 2018, in connection with a rights offering of 267,853 shares of its Common Stock (the “2018 Rights Offering”),
the Company issued to investors warrants to purchase 267,853 shares of its Common Stock. Terms used but not otherwise defined
herein will have the meaning given them in the warrant, attached as Exhibit 4.1 to our Form 10-Q filed on August 14, 2018. This
warrant has substantially similar terms as the July 2019 Warrant described above, except that this warrant has an exercise price
of $23.00 per share and will expire August 13, 2023. In addition, this warrant has the following terms:

 

Right
of Redemption. Subject to certain limitations in the warrant, the Company may redeem for consideration equal to $0.01 all
of the outstanding warrants for which a Notice of Exercise has not been delivered if, six months after the warrants become exercisable,
(1) the VWAP for each of five consecutive trading days is $57.50 and (2) the holders of the warrants have no material, non-public
information from the Company. The Company must provide at least thirty days’ notice of the date of such redemption. Following
such notice and prior to the date of redemption, the warrants may be exercised for cash in accordance with the terms therein.

 

Common
Stock Warrants Issued to Dealer-Manager in August 2018 Rights Offering

 

In
connection with the closing of the 2018 Rights Offering, the Company also issued a warrant to purchase 13,393 shares of Common
Stock to Maxim Partners LLC, an affiliate of the dealer-manager of the 2018 Rights Offering. The warrant was issued in reliance
on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated
thereunder. Terms used but not otherwise defined herein will have the meaning given them in the warrant, attached as Exhibit 4.2
to our Form 10-Q filed on August 14, 2018. This warrant has substantially similar terms as the warrants described in the August
2018 Rights Offering described above, except that this warrant has an exercise price of $34.50 per share, will expire July 25,
2023, and does not have a redemption feature.

 

Common
Stock Warrants Issued in June 2018 Private Placement

 

On
June 20, 2018, the Company issued warrants to purchase a total of 56,696 shares of Common Stock to an investor in a private placement.
The warrants were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and
Rule 506(b) of Regulation D promulgated thereunder. Terms used but not otherwise defined herein will have the meaning given them
in the warrant, attached as Exhibit 4.1 to our Form 8-K filed on June 20, 2018.

 

Duration
and Exercise Price. The warrants have an exercise price of $36.40 per share and are exercisable after December 20, 2018. The
warrants will expire in December 2023.

 

Adjustment.
For so long as the warrants remain outstanding, the exercise price and number of shares of Common Stock issuable upon exercise
of the warrant is subject to adjustment as follows: (a) as the Company’s board of directors deems appropriate, or (b) upon
subdivision (by stock spilt, stock dividend, recapitalization, or otherwise) or combination (by reverse stock split or otherwise)
of shares of Common Stock.

 

    3

     

    

 

Rights
upon Distribution of Assets. In the event that the Company declares or makes any dividend or other distribution of its assets
to holders of its Common Stock, the warrant holder will be entitled to participate in such distribution to the same extent that
such holder would have participated therein if the holder had held the number of shares of Common Stock acquirable upon exercise
of the warrant.

 

Fundamental
Transaction. In the event of a Fundamental Transaction, as described in the warrants and generally including the sale, transfer
or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another
person or reorganization, recapitalization or reclassification or the acquisition of our outstanding Common Stock which results
in any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding Common Stock, the
holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash, assets
or other property that the holders would have received had they exercised the warrants immediately prior to such Fundamental Transaction.
Subject to certain limitations, in the event of a Fundamental Transaction the warrant holder may at its option require the Company
or any Successor Entity to purchase the warrant from the holder by paying to the holder an amount of cash equal to the Black Scholes
Value of the remaining unexercised portion of the warrant on the date of the consummation of the Fundamental Transaction.

 

Purchase
Right. Any time that the Company grants, issues, or sells any securities pro rata to all of the record holders of the Common
Stock (the “June 2018 Purchase Right”), the holder of the warrant will be entitled to acquire the aggregate June 2018
Purchase Rights which the holder could have acquired if the holder had held the number of shares of Common Stock acquirable upon
exercise of the warrant.

 

Transferability.
Subject to applicable laws and restrictions on transfer, the warrant may be transferred at the option of the holder. The warrants
are not listed on any securities exchange or nationally recognized trading system.

 

Exercisability.
After the Initial Exercisability Date, the warrants will be exercisable, at the option of each holder, in whole or in part, by
delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased
upon such exercise. If, at the time a holder exercises its warrant, a registration statement registering the issuance of the shares
of Common Stock underlying the warrants under the Securities Act is not then effective or available and an exemption from registration
under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such
exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in
the warrant.

 

Limitations
on Exercise. A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder
would own more than 4.99% of the outstanding Common Stock after exercise, except that upon at least 61 days’ prior notice
from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s
warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the warrants. No fractional shares of Common Stock
will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will round up to the next whole
share.

 

Right
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of
our Common Stock, the holders of the warrants do not have the rights or privileges of holders of our Common Stock, including any
voting rights, unless and until they exercise their warrants.

 

Waivers
and Amendments. Subject to certain exceptions, any term of the warrants may be amended or waived with our written consent
and the written consent of the holders.

 

Failure
to Timely Deliver Securities. Upon exercise of the warrant by the holder, if the Company or its transfer agent fails to deliver
the securities to holder by the required share delivery date set forth in the warrant, then, generally, the holder may require
the Company to pay to the holder an amount in cash to make the investor whole in connection with the Company’s failure to
timely deliver securities.

 

    4

     

    

 

Common
Stock Warrants Issued to Participants in November 2017 Offering

 

On
November 21, 2017, in its public offering of Common Stock, the Company issued warrants to purchase a total of 232,875 shares of
Common Stock to investors. Terms used but not otherwise defined herein will have the meaning given them in the warrant, attached
as Exhibit 4.2 to our Form 8-K filed on November 17, 2017.

 

Duration
and Exercise Price. The warrants have an exercise price of $30.00 per share, are exercisable immediately and will expire in
November 2022, on the fifth anniversary of the original issuance date.

 

Adjustment.
For so long as the warrants remain outstanding, the exercise price and number of shares of Common Stock issuable upon exercise
of the warrant is subject to adjustment as follows: (a) as the Company’s board of directors deems appropriate, (b) upon
subdivision (by stock spilt, stock dividend, recapitalization, or otherwise) or combination (by reverse stock split or otherwise)
of shares of Common Stock, (c) upon the issuance or announcement of contemplated issuance (“Dilutive Issuance”) of
shares of Common Stock, options or convertible securities for consideration per share less than the price equal to the exercise
price of the warrants, except for certain Excluded Securities issued in connection with an Approved Equity Plan, (d) at the option
of the warrant holder upon the Company’s entering into an agreement to issue securities that are issuable at a price which
varies or may vary with the market price of the Company’s Common Stock (the “Variable Price”), and (e) in certain
cases upon granting of stock appreciation rights, phantom stock rights or other rights with equity features, except for those
granted pursuant to an Approved Equity Plan. For the adjustments summarized in (c) above, the exercise price of the warrants outstanding
generally will adjust upon the record date of such issuance to the New Issuance Price (as defined in the warrant, and which will
be based on the net price at which new securities in the Dilutive Issuance are issued or subsequently adjusted, and in some cases,
the lower of such price or the weighted average trading price of the Common Stock for the four trading days immediately following
public announcement of the Dilutive Issuance). For the adjustments summarized in (d) above, the holder may, at its option, elect
to adjust the exercise price of the warrants to the Variable Price of securities sold by the Company pursuant to the agreement.
Any adjustment made upon announcement or pursuant to a Dilutive Issuance will not be readjusted in the event that such Dilutive
Issuance does not occur.

 

Rights
upon Distribution of Assets. In the event that the Company declares or makes any dividend or other distribution of its assets
to holders of its Common Stock, the warrant holder will be entitled to participate in such distribution to the same extent that
such holder would have participated therein if the holder had held the number of shares of Common Stock acquirable upon exercise
of the warrant.

 

Fundamental
Transaction. In the event of a Fundamental Transaction, as described in the warrants and generally including the sale, transfer
or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another
person or reorganization, recapitalization or reclassification or the acquisition of our outstanding Common Stock which results
in any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding Common Stock, the
holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash, assets
or other property that the holders would have received had they exercised the warrants immediately prior to such Fundamental Transaction.
Subject to certain limitations, in the event of a Fundamental Transaction the warrant holder may at its option require the Company
or any Successor Entity to purchase the warrant from the holder by paying to the holder an amount of cash equal to the Black Scholes
Value of the remaining unexercised portion of the warrant on the date of the consummation of the Fundamental Transaction.

 

Purchase
Right. Any time that the Company grants, issues, or sells any securities pro rata to all of the record holders of the Common
Stock (the “November 2017 Purchase Right”), the holder of the warrant will be entitled to acquire the aggregate November
2017 Purchase Rights which the holder could have acquired if the holder had held the number of shares of Common Stock acquirable
upon exercise of the warrant.

 

Transferability.
Subject to applicable laws and restrictions on transfer, the warrant may be transferred at the option of the holder. The warrants
are not listed on any securities exchange or nationally recognized trading system.

 

Exercisability.
The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise. If, at the time
a holder exercises its warrant, a registration statement registering the issuance of the shares of Common Stock underlying the
warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act
is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to
us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either
in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the warrant.

 

    5

     

    

 

Limitations
on Exercise. A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder
would own more than 4.99% of the outstanding Common Stock after exercise, except that upon at least 61 days’ prior notice
from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s
warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the warrants. No fractional shares of Common Stock
will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will either pay the holder an amount
in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.

 

Right
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of
our Common Stock, the holders of the warrants do not have the rights or privileges of holders of our Common Stock, including any
voting rights, unless and until they exercise their warrants.

 

Limitation
on Variable Rate Transactions. The Company may not effect or enter into any agreement to sell securities in a Variable Rate
Transaction.

 

Waivers
and Amendments. Subject to certain exceptions, any term of the warrants may be amended or waived with our written consent
and the written consent of the holders.

 

Failure
to Timely Deliver Securities. Upon exercise of the warrant by the holder, if the Company or its transfer agent fails to deliver
the securities to holder by the required share delivery date set forth in the warrant, or if the Company did not provide the required
notice to holder that a registration statement covering the issuance of the warrant shares subject to the exercise notice is not
available and the Company is unable to deliver the securities without any restrictive legend (each, an Exercise Failure), then,
generally, the holder may rescind the exercise in whole or in part or may require the Company to pay to the holder an amount in
cash to make the investor whole in connection with the Company’s failure to timely deliver securities.

 

Common
Stock Warrant Issued to Underwriter of November 2017 Offering

 

In
November 2017, the Company issued to Roth Capital Partners, LLC, as underwriter, a warrant to purchase 27,000 shares of Common
Stock, which shares include a warrant (in the form of warrant issued to the public) to purchase an additional 20,250 shares of
Common Stock in connection with our November 2017 offering. The warrant was issued in reliance on the exemption from registration
provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. Terms used but not otherwise
defined herein will have the meaning given them in the warrant.

 

Duration
and Exercise Price. The warrants have an exercise price of $30.00 per share, are exercisable immediately and will expire in
November 2022, on the fifth anniversary of the original issuance date. The terms of the warrant are limited by FINRA Rule 5110(f)(2)(G),
which provide, among others, that the warrant may not be exercised more than five years from the date that the registration statement
registering the warrant was declared effective by the SEC.

 

Adjustment.
The exercise price and number of shares of Common Stock issuable upon exercise of the warrant is subject to adjustment as follows:
(a) as the Company’s board of directors deems appropriate, or (b) upon a stock dividend, stock split, reorganization, subdivision
or combination of shares of Common Stock.

 

Fundamental
Transaction. In the event of a Fundamental Transaction, as described in the warrants and generally including any reorganization,
recapitalization or reclassification of our Common Stock, the sale, transfer or other disposition of all or substantially all
of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our
outstanding Common Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding
Common Stock, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities,
cash or other property that the holders would have received had they exercised the warrants immediately prior to such Fundamental
Transaction.

 

Purchase
Right. Any time that the Company grants, issues, or sells any securities pro rata to all of the record holders of the Common
Stock (the “November Purchase Right”), the holder of the warrant will be entitled to acquire the aggregate November
Purchase Rights which the holder could have acquired if the holder had held the number of shares of Common Stock acquirable upon
exercise of the warrant.

 

Transferability.
Subject to applicable laws and restrictions on transfer, the warrant may be transferred at the option of the holder after the
expiration of the Lock-Up Period, which is 180 days after the registration statement registering the warrant became effective.
The warrants are not listed on any securities exchange or nationally recognized trading system.

 

    6

     

    

 

Exercisability.
The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise. If, at the time
a holder exercises its warrant, a registration statement registering the issuance of the shares of Common Stock underlying the
warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act
is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to
us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either
in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the warrant.

 

Limitations
on Exercise. A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder
would own more than 4.99% of the outstanding Common Stock after exercise, except that upon at least 61 days’ prior notice
from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s
warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the warrants. No fractional shares of Common Stock
will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will either pay the holder an amount
in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.

 

Right
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of
our Common Stock, the holders of the warrants do not have the rights or privileges of holders of our Common Stock, including any
voting rights, unless and until they exercise their warrants.

 

Waivers
and Amendments. Subject to certain exceptions, any term of the warrants may be amended or waived with our written consent
and the written consent of the holder.

 

Other
Warrants

 

Prior
to our initial public offering and in connection with entering into a license agreement, we issued warrants to purchase 750 shares
of Common Stock to the University of Arizona. Terms used but not otherwise defined herein will have the meaning given them in
the warrant.

 

Duration
and Exercise Price. The warrants expire in June 2020 and have an exercise price of $150.00 per share.

 

Adjustment.
The exercise price and number of shares of Common Stock issuable upon exercise of the warrant is subject to adjustment upon a
stock dividend, stock split, reorganization, subdivision, combination, reclassification or reorganization of shares of Common
Stock.

 

Terminating
Change. In the event of a Terminating Change, defined to include any consolidation, merger, sale of all or substantially all
of the assets of the Company, or capital reorganization or certain reclassifications of the Company’s stock, the Company
will pay to the holder the fair market value of the warrant shares immediately prior to the Terminating Change.

 

Notice.
The warrant holder is entitled to notice of certain transactions, including when: (i) the Company takes a record of holders of
its Common Stock for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any
right to subscribe for or purchase any shares of stock or any class or other securities, (ii) the Company offers to sell certain
Company securities, (iii) the Company’s Common Stock is reorganized or reclassified, (iv) any consolidation or merger of
the Company or any conveyance of all or substantially all of the assets of the Company, (v) the Company undergoes a voluntary
or involuntary dissolution, liquidation or winding up of the Company.

 

Transferability.
Subject to applicable laws and restrictions on transfer, the warrant may be transferred at the option of the holder.

 

Exercisability.
The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise. At the election
of the holder, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the
aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number
of shares of Common Stock determined according to a formula set forth in the warrant.

 

    7

     

    

 

Right
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of
our Common Stock, the holders of the warrants do not have the rights or privileges of holders of our Common Stock, including any
voting rights, unless and until they exercise their warrants.

 

Waivers
and Amendments. Subject to certain exceptions, any term of the warrants may be amended or waived with our written consent
and the written consent of the holder.

 

IPO
Underwriter Warrant

 

In
connection with our initial public offering in December 2016, we issued warrants to purchase 9,375 shares of our Common Stock
to Roth Capital Partners LLC.

 

Duration
and Exercise Price. The warrants have an exercise price of $192.00 per share. The warrant was fully vested and exercisable
on the date of grant and will expire in December 2021, on the fifth anniversary of the original issuance date.

 

Adjustment.
The exercise price and number of shares of Common Stock issuable upon exercise of the warrant is subject to adjustment as follows:
(a) as the Company’s board of directors deems appropriate, or (b) upon a stock dividend, stock split, reorganization, subdivision
or combination of shares of Common Stock.

 

Rights
upon Distribution of Assets. In the event that the Company declares or makes any dividend or other distribution of its assets
to holders of its Common Stock, the warrant holder will be entitled to participate in such distribution to the same extent that
such holder would have participated therein if the holder had held the number of shares of Common Stock acquirable upon exercise
of the warrant.

 

Fundamental
Transaction. In the event of a Fundamental Transaction, as described in the warrants and generally including any reorganization,
recapitalization or reclassification of our Common Stock, the sale, transfer or other disposition of all or substantially all
of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our
outstanding Common Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding
Common Stock, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities,
cash or other property that the holders would have received had they exercised the warrants immediately prior to such Fundamental
Transaction. The Company may not enter into a Fundamental Transaction unless the successor entity assumes all obligations of the
Company under the warrant pursuant to an agreement in form and substance reasonably satisfactory to the holder.

 

Purchase
Right. Any time that the Company grants, issues, or sells any securities pro rata to all of the record holders of the Common
Stock (the “December 2016 Purchase Right”), the holder of the warrant will be entitled to acquire the aggregate December
2016 Purchase Rights which the holder could have acquired if the holder had held the number of shares of Common Stock acquirable
upon exercise of the warrant.

 

Transferability.
Subject to applicable laws and restrictions on transfer, the warrant may be transferred at the option of the holder. The warrants
are not listed on any securities exchange or nationally recognized trading system.

 

Exercisability.
The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise. If, at the time
a holder exercises its warrant, a registration statement registering the issuance of the shares of Common Stock underlying the
warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act
is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to
us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either
in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the warrant.

 

Limitations
on Exercise. A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder
would own more than 4.99% of the outstanding Common Stock after exercise, except that upon at least 61 days’ prior notice
from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s
warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the warrants. No fractional shares of Common Stock
will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will either pay the holder an amount
in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.

 

    8

     

    

 

Right
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of
our Common Stock, the holders of the warrants do not have the rights or privileges of holders of our Common Stock, including any
voting rights, unless and until they exercise their warrants.

 

Waivers
and Amendments. Subject to certain exceptions, any term of the warrants may be amended or waived with our written consent
and the written consent of the holder.

 

For
additional information about outstanding warrants, please read “Item 1. Financial Statements — Notes to Condensed
Financial Statements — Note 11. Common Stock Warrants and Common Stock Warrant Liability” in our Quarterly Report
on Form 10-Q filed with the SEC on May 15, 2018, as amended by Form 10-Q/A filed with the SEC on May 22, 2018.

 

Registration
Rights

 

The
Common Stock warrants issued under our 2018 Rights Offering provide for a registration right. During any period that the holders
of these warrants wish to exercise their warrants and (1) we do not have an effective registration statement or current prospectus
relating thereto (2) and an exemption to registration is not available in the opinion of the holder’s counsel, then we must
immediately file a registration statement and use our best efforts to have it declared effective within 30 days.

 

Anti-Takeover
Provisions

 

Certificate
of Incorporation and Bylaws

 

Because
our stockholders do not have cumulative voting rights, our stockholders holding a majority of the outstanding shares of Common
Stock outstanding will be able to satisfy the quorum requirement and be able to elect all of our directors by a plurality of the
voting power of the shares present in person or by proxy. Our amended and restated certificate of incorporation and amended and
restated bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by written
consent. A special meeting of stockholders may be called by a resolution adopted by a majority of our board, our chair of the
board, our chief executive officer or the president in absence of the chief executive officer. Any power of the stockholders to
call a special meeting is specifically denied by the terms of our amended and restated certificate of incorporation.

 

Our
board of directors is divided into three classes with staggered three-year terms. These provisions make it more difficult for
our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing
our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could
also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization
of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights
or preferences that could impede the success of any attempt to obtain control of us.

 

These
provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its
policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions
are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may
be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our
shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence,
these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover
attempts.

 

Section
203 of the Delaware General Corporation Law

 

We
are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any
business combination with any interested stockholder for a period of three years after the date that such stockholder became an
interested stockholder, with the following exceptions:

 

	 	●	Before
    such date, the board of directors of the corporation approved either the business combination or the transaction that resulted
    in the stockholder becoming an interested stockholder;
	 	 	 
	 	●	Upon
    closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes
    of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those
    shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants
    do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or
    exchange offer; or
	 	 	 
	 	●	On
    or after such date, the business combination is approved by the board of directors and authorized at an annual or special
    meeting of the stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-third percent
    (66 2/3%) of the outstanding voting stock that is not owned by the interested stockholder.

 

    9

     

    

 

In
general, Section 203 defines business combination to include the following:

 

	 	●	Any
    merger or consolidation involving the corporation and the interested stockholder;
	 	 	 
	 	●	Any
    sale, lease, exchange, mortgage, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving
    the interested stockholder;
	 	 	 
	 	●	Subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;
	 	 	 
	 	●	Any
    transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class
    or series of the corporation beneficially owned by the interested stockholder; or
	 	 	 
	 	●	The
    receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits
    by or through the corporation.

 

In
general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s
affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder
status did own, 15% or more of the outstanding voting stock of the corporation.

 

Choice
of Forum

 

Our
amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive
forum for any derivative action or proceeding brought on our behalf; any action asserting a claim of a breach of fiduciary duty
owed by any director, officer or other employee to the Company or the Company’s stockholders; any action asserting a claim
against us or any of our directors, officers or other employees arising pursuant to the Delaware General Corporation Law, our
amended and restated certificate of incorporation or our amended and restated bylaws; or any action or proceeding asserting a
claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.

 

Listing
of our Common Stock

 

Our
Common Stock is listed on The Nasdaq Capital Market under the symbol “SNES.”

 

 

10Exhibit 4.6

 

SENESTECH, INC.

2018 EQUITY INCENTIVE PLAN

 

RESTRICTED STOCK UNIT GRANT NOTICE

 

Senestech,
Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”),
hereby grants to you (“Grantee”) a Restricted Stock Unit Award for the number of Restricted Stock Units
(the “Restricted Stock Units”) set forth below. Each Restricted Stock Unit represents the right to receive
one share of Common Stock, subject to the terms and conditions set forth herein.

 

The Restricted Stock Units are subject to all
of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (this “Notice”) and
in the Restricted Stock Unit Agreement and the Plan, which are attached hereto and incorporated herein in their entirety. Capitalized
terms not explicitly defined in this Notice or in the Restricted Stock Unit Agreement but defined in the Plan have the same definitions
as in the Plan. If there is any conflict between the terms in this Notice and the Plan, the terms of the Plan will control.

 

	
        Grantee:
	 
	 	 
	Date of Grant:	 
	 	 
	Number of Restricted Stock Units:	 
	 	 
	Vesting Commencement Date:	 
	 	 
	Vesting Schedule:	[Insert vesting schedule:
	 	 
	 	 
	 	Vesting is subject to Continuous Service through each applicable vesting date.]

 

Additional Terms/Acknowledgements: You
acknowledge receipt of, and understand and agree to, this Notice, the Restricted Stock Unit Agreement and the Plan. You acknowledge
and agree that this Notice and the Restricted Stock Unit Agreement may not be modified, amended or revised except as provided in
the Plan. You further acknowledge that as of the Date of Grant, this Notice, the Restricted Stock Unit Agreement and the Plan set
forth the entire understanding between you and the Company regarding the Restricted Stock Units and supersede all prior oral and
written agreements, promises and/or representations on that subject with the exception of any provisions applicable to the Restricted
Stock Units in the agreements set forth below. By accepting the Restricted Stock Units, you consent to receive documents related
to current or future participation in the Plan by electronic delivery and to participate in the Plan through an on-line or electronic
system established and maintained by the Company or another third party designated by the Company.

 

	Other
Agreements:    	 

 

	Senestech, Inc.	 	Grantee:
	 	 	 
	By:	          	 	By:	            
	Signature	 	Signature
	 	 	 
	Title:	 	 	Date:	 
	 	 	 	 	 
	Date:	 	 	 	 

 

Attachments:
Restricted Stock Unit Agreement and 2018 Equity Incentive Plan

 

     

     

    

 

ATTACHMENT I

 

SENESTECH, INC.

2018 EQUITY INCENTIVE PLAN

 

RESTRICTED STOCK UNIT AGREEMENT

 

Pursuant to your Restricted
Stock Unit Grant Notice (the “Grant Notice”)
and this Restricted Stock Unit Agreement (together with the Grant Notice, this “Agreement”), Senestech,
Inc. (the “Company”) has granted you a Restricted Stock Unit Award under its 2018 Equity Incentive
Plan (the “Plan”) for the number of Restricted Stock Units (the “Restricted Stock Units”)
indicated in your Grant Notice. The Restricted Stock Units are granted to you effective as of the date of grant set forth in the
Grant Notice (the “Date of Grant”). Capitalized terms not explicitly defined in this Restricted Stock
Unit Agreement or the Grant Notice but defined in the Plan have the same definitions as in the Plan.

 

The details of your Restricted Stock Units,
in addition to those set forth in the Grant Notice and the Plan, are as follows:

 

1. Vesting.
The Restricted Stock Units will vest as provided in your Grant Notice. Once vested, the Restricted Stock Units become “Vested
Units.” The foregoing vesting schedule notwithstanding, if your Continuous Service terminates for any reason other
than as a result of your death or Disability at any time before all your Restricted Stock Units have vested, your unvested Restricted
Stock Units will be automatically forfeited upon such termination of Continuous Service and neither the Company nor any Affiliate
will have any further obligations to you under this Agreement. The period during which the Restricted Stock Units vest is the “Restricted
Period.”

 

2. Separate
Account. The Restricted Stock Units will be credited to a separate account maintained for you on the books and records
of the Company (the “Account”). All amounts credited to the Account will continue for all purposes to
be part of the general assets of the Company.

 

3.
Consideration. The grant of the Restricted Stock Units is made in consideration
of the services rendered or to be rendered by you to the Company or an Affiliate.

 

4. Restrictions.
Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period and until such time as the Restricted
Stock Units are settled in accordance with Section 6, the Restricted Stock Units or the rights relating thereto may not be assigned,
alienated, pledged, attached, sold or otherwise transferred or encumbered by you. Any attempt to assign, alienate, pledge, attach,
sell or otherwise transfer or encumber the Restricted Stock Units or the rights relating thereto will be wholly ineffective and,
if any such attempt is made, the Restricted Stock Units will be forfeited by you and all of your rights to such units will immediately
terminate without any payment or consideration by the Company.

 

5.
Rights as Stockholder; Dividend Equivalents.

 

5.1 You
will not have any rights of a stockholder with respect to the shares of Common Stock underlying the Restricted Stock Units unless
and until the Restricted Stock Units vest and are settled by the issuance of shares of Common Stock.

 

5.2 Upon
and following the settlement of the Restricted Stock Units, you will be the record owner of the shares of Common Stock underlying
the Restricted Stock Units unless and until such shares are sold or otherwise disposed of, and as record owner you will be entitled
to all rights of a stockholder of the Company (including voting rights).

 

    2

     

    

 

5.3 You
will not be entitled to any dividend equivalents with respect to the Restricted Stock Units to reflect any dividends payable on
shares of Common Stock.

 

6.
Settlement of Restricted Stock Units.

 

6.1 Subject
to Section 9 hereof, promptly following the vesting date (but generally in no event more than five (5) business days thereafter),
the Company will (a) issue and deliver to you the number of shares of Common Stock equal to the number of Vested Units; and (b)
enter your name on the books of the Company as the stockholder of record with respect to the shares of Common Stock delivered to
you.

 

6.2 If
you are deemed a “specified employee” within the meaning of Section 409A of the Code, as determined by the Committee,
at a time when you become eligible for settlement of the Restricted Stock Units upon your “separation from service”
within the meaning of Section 409A of the Code, then to the extent necessary to prevent any accelerated or additional tax under
Section 409A of the Code, such settlement will be delayed until the earlier of: (a) the date that is six months following your
separation from service and (b) your death.

 

7.
No Right to Continued Service. Neither the Plan
nor this Agreement confers upon you any right to be retained in any position, as an Employee, Consultant or Director of the Company
or an Affiliate. Further, nothing in the Plan or this Agreement will be construed to limit the discretion of the Company or an
Affiliate to terminate your Continuous Service at any time, with or without Cause.

 

8.
Adjustments. If any change is made to the outstanding Common Stock or
the capital structure of the Company, if required, the Restricted Stock Units will be adjusted or terminated in any manner as
contemplated by Section 9 of the Plan.

 

9.
Tax Liability and Withholding.

 

9.1 You
agree to make adequate arrangements satisfactory to the Company prior to any relevant taxable or tax withholding event, as applicable,
to satisfy all applicable income tax, social insurance, payroll tax or other tax-related withholding items (“Tax-Related
Items”). In this regard, you authorize the Company to deduct from any compensation paid to you the amount of Tax-Related
Items in respect of the Restricted Stock Units and to take all such other action as the Company deems necessary to satisfy all
obligations for the payment of such Tax-Related Items. Alternatively, or in addition, the Company, in its sole discretion and without
prior authorization from you, may satisfy any Tax-Related Items by any of the following means, or by a combination of such means:

 

(a) by
withholding shares of Common Stock from the shares of Common Stock otherwise issuable or deliverable to you as a result of the
vesting of the Restricted Stock Units; provided, however, that no shares of Common Stock will be withheld with a value exceeding
the minimum amount of tax required to be withheld by law; or

 

(b) By
selling or arranging for the sale of shares of Common Stock otherwise issuable or deliverable to you as a result of the vesting
of the Restricted Stock Units.

 

    3

     

    

 

9.2 To
the extent not prohibited by applicable legal or regulatory provisions, the Company intends that Tax-Related Items be satisfied
in accordance with Section 9.1(a) above, unless the Company determines otherwise at any time. Notwithstanding any action the Company
takes with respect to any Tax-Related Items, the ultimate liability for all Tax-Related Items is and remains your responsibility
and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with
the grant, vesting or settlement of the Restricted Stock Units or the subsequent sale of any shares; and (b) does not commit to
structure the Restricted Stock Units to reduce or eliminate your liability for Tax-Related Items.

 

10.
Compliance with Law. The issuance and transfer of shares of Common Stock
is subject to compliance by the Company and you with all applicable requirements of federal and state securities laws and with
all applicable requirements of any stock exchange on which the Company’s shares of Common Stock may be listed. No shares
of Common Stock will be issued or transferred unless and until any then applicable requirements of state and federal laws and
regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel.

 

11.
Notices. Any notices provided for in this Agreement or the Plan will
be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered
by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the
last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to
participation in the Plan and the Restricted Stock Units by electronic means.

 

12. Governing
Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware without
regard to conflict of law principles.

 

13. Interpretation.
Any dispute regarding the interpretation of this Agreement must be submitted by you or the Company to the Committee for review.
The resolution of such dispute by the Committee will be final and binding on you and the Company.

 

14. Governing
Plan Document. The Restricted Stock Units are subject to the provisions of the Plan, the provisions of which are hereby
made a part of this Agreement, and are further subject to all interpretations, amendments, rules and regulations, which may from
time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of this Agreement
and those of the Plan, the provisions of the Plan will control.

 

15. Successors
and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this
Agreement will be binding upon you and your beneficiaries, executors, administrators and the person(s) to whom the Restricted
Stock Units may be transferred by will or the laws of descent or distribution.

 

16. Severability.
The invalidity or unenforceability of any provision of the Plan or this Agreement will not affect the validity or enforceability
of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement will be severable and
enforceable to the extent permitted by law.

 

17. Discretionary
Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in
its discretion. The grant of the Restricted Stock Units in this Agreement does not create any contractual right or other right
to receive any Restricted Stock Units or other Stock Awards in the future. Future Stock Awards, if any, will be at the sole discretion
of the Company. Any amendment, modification, or termination of the Plan will not constitute a change or impairment of the terms
and conditions of your employment or service with the Company.

 

    4

     

    

 

18. Restricted
Stock Units Not a Service Contract.
The Restricted Stock Units are not an employment or service contract, and nothing in the Restricted Stock Units will
be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate,
or of the Company or an Affiliate to continue your employment. In addition, nothing in the Restricted Stock Units will obligate
the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship
that you might have as a Director or Consultant for the Company or an Affiliate.

 

19. Amendment.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Restricted Stock Units, prospectively or retroactively;
provided, that, no such amendment will adversely affect your material rights under this Agreement without your consent.

 

20. Tax
Consequences; Section 409A. You agree that the Company does not have a duty to design or administer the Plan or its
other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company,
or any of its Officers, directors, Employees or Affiliates related to tax liabilities arising from the Restricted Stock Units
or your other compensation. In particular, this Agreement is intended to comply with Section 409A of the Code or an exemption
thereunder and will be construed and interpreted in a manner that is consistent with the requirements for avoiding additional
taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the
payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event will the Company be liable
for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by you on account of non-compliance
with Section 409A of the Code. You acknowledge that there may be adverse tax consequences upon the vesting or settlement of the
Restricted Stock Units or disposition of the underlying shares and that you have been advised to consult a tax advisor prior to
such vesting, settlement or disposition.

 

21. No
Impact on Other Benefits. The value of your Restricted Stock Units is not part of your normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.

 

22. Counterparts.
The Grant Notice may be executed in counterparts, each of which will be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to the Grant Notice transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

 

    5

     

    

 

ATTACHMENT II

 

2018 EQUITY INCENTIVE PLAN

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]